Abstract
Background
Postural orthostatic tachycardia syndrome (POTS) is a form of orthostatic intolerance, and its incidence in children is approximately 6.8% [1]. The pathogenesis of POTS is complex with multiple, overlapping, interacting pathophysiological mechanisms. Although the specific pathogenic mechanism has remained perplexing, with the discovery of various gasotransmitters and biological peptides, the vascular dysfunction has aroused overwhelming attention.
Data sources
On the basis of searching in a wide range of recent original literatures, we reviewed the pathogenesis of vascular dysfunction in children with POTS.
Results
The flow-mediated vasodilation of POTS patients was greater than that of healthy controls, and the vasodilator factors were increased in patients with POTS under basal condition or under a standing position, while the vasoconstriction factors were reduced.
Conclusions
Vascular dysfunction, as one of pathogenesis in pediatric POTS patients, affects the occurrence and development of diseases through a variety of factors.
Similar content being viewed by others
References
Lin J, Han Z, Li X, Ochs T, Zhao J, Zhang X, et al. Risk factors for postural tachycardia syndrome in children and adolescents. PLoS ONE. 2014;9:e113625.
Kizilbash SJ, Ahrens SP, Bruce BK, Chelimsky G, Driscoll SW, Harbeck-Weber C, et al. Adolescent fatigue, POTS, and recovery: a guide for clinicians. Current Curr Probl Pediatr Adolesc Health Care. 2014;44:108–33.
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72.
Stewart JM, Weldon A. Vascular perturbations in the chronic orthostatic intolerance of the postural orthostatic tachycardia syndrome. J Appl Physiol. 1985;2000(89):1505–12.
Liao Y, Chen S, Liu X, Zhang Q, Ai Y, Wang Y, et al. Flow-mediated vasodilation and endothelium function in children with postural orthostatic tachycardia syndrome. Am J Cardiol. 2010;106:378–82.
Stewart JM, Weldon A. Reflex vascular defects in the orthostatic tachycardia syndrome of adolescents. J Appl Physiol. 1985;2001(90):2025–32.
Stewart JM, Medow MS, Glover JL, Montgomery LD. Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2006;290:H665–73.
Víteček J, Lojek A, Valacchi G, Kubala L. Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediat Inflamm. 2012;2012:318087.
Garland EM, Winker R, Williams SM, Jiang L, Stanton K, Byrne DW, et al. Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension. 2005;46:1103–10.
Gamboa A, Okamoto LE, Raj SR, Diedrich A, Shibao CA, Robertson D, et al. Nitric oxide and regulation of heart rate in patients with postural tachycardia syndrome and healthy subjects. Hypertension. 2013;61:376–81.
Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001;20:6008–16.
Huang J, Luo YL, Hao Y, Zhang YL, Chen PX, Xu JW, et al. Cellular mechanism underlying hydrogen sulfide induced mouse tracheal smooth muscle relaxation: role of BKCa. Eur J Pharmacol. 2014;741:55–63.
Du J, Yan H, Tang C. Endogenous H2S is involved in the development of spontaneous hypertension. Beijing Da Xue Xue Bao. 2003;35:102 (in Chinese).
Du J, Hui Y, Cheung Y, Bin G, Jiang H, Chen X, et al. The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels. 2004;19:75–80.
Zhang F, Li X, Stella C, Chen L, Liao Y, Tang C, et al. Plasma hydrogen sulfide in differential diagnosis between vasovagal syncope and postural orthostatic tachycardia syndrome in children. J Pediatr. 2012;160:227–31.
Yang J, Zhao J, Du S, Liu D, Fu C, Li X, et al. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride. J Pediatr. 2013;163(1169–73):e2.
Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 2004;279:7264–74.
Li H, Liao Y, Han Z, Wang Y, Liu P, Zhang Q, et al. Changes of plasma intermedin during head-up tilt test in children with postural tachycardia syndrome and its significance. Zhonghua Er Ke Za Zhi. 2015;53:375–8 (in Chinese).
Zhao J, Du S, Yang J, Lin J, Tang C, Du J, et al. Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children. Am J Cardiol. 2014;114:601–5.
Fedorowski A, Burri P, Struck J, Juul-Möller S, Melander O. Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort. J Intern Med. 2013;273:359–67.
White M, Cernacek P, Courtemanche M, Stewart D, Talajic M, Mikes E, et al. Impaired endothelin-1 release in tilt-induced syncope. Am J Cardiol. 1998;81:460–4.
Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol. 2006;17:108–12.
Bondanelli M, Alboni P, Margutti A, Franceschetti P, Dinelli M, Gruppillo P, et al. Plasma galanin response to head-up tilt in normal subjects and patients with recurrent vasovagal syncope. Metabolism. 2003;52:315–21.
Liao Y, Du JB, Tang CS, Jin HF. Change and significance in the levels of plasma urotensin II and catestatin in children with postural orthostatic tachycardia syndrome. Beijing Da Xue Xue Bao. 2011;43:436–9 (in Chinese).
Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, et al. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000;343:1008–14.
Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41–63.
Gibbons CH, Bonyhay I, Benson A, Wang N, Freeman R. Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome. PLoS ONE. 2013;8:e84716.
Wallman D, Weinberg J, Hohler AD. Ehlers–Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340:99–102.
Grigoriou E, Boris JR, Dormans JP. Postural orthostatic tachycardia syndrome (POTS): association with Ehlers–Danlos syndrome and orthopaedic considerations. Clin Orthop Relat Res. 2015;473:722–8.
Mathias CJ, Low DA, Iodice V, Owens AP, Kirbis M, Grahame R. Postural tachycardia syndrome-current experience and concepts. Nat Rev Neurol. 2011;8:22–34.
Authors contributions
Hongfang Jin and Junbao Du contributed to the concept and design. Wei Bai contributed to the collection and summarization of previous articles. Wei Bai and Siyao Chen drafted the article. Siyao Chen, Hongfang Jin and Junbao Du revised the manuscript. All authors approved the final version.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by Beijing Municipal Science and Technology Major Project (Z171100001017253) and National Youth Top-notch Talent Support Program.
Ethical approval
Not needed.
Conflict of interest
None of the authors has any financial, personal, or professional interests that could be construed to have influenced the paper.
Rights and permissions
About this article
Cite this article
Bai, W., Chen, SY., Jin, HF. et al. Vascular dysfunction of postural tachycardia syndrome in children. World J Pediatr 14, 13–17 (2018). https://doi.org/10.1007/s12519-017-0104-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-017-0104-8